Hong Kong firms eye proprietary Chinese medicine opportunities on the mainland: HKTDC
Beijing’s move to simplify the process for approving oral proprietary Chinese medicine (PCM) from Hong Kong to be sold across the border has created new opportunities for firms in the city to exploit the mainland’s 450 billion yuan (US$62.8 billion) market, according to Hong Kong’s trade promotion body. The streamlined procedures have opened a more…